The main research focus is the development, preclinical and clinical validation of T-cell based gene therapy to treat cancer. I had the privilege to initiate the suicide gene therapy approach applied to allogeneic stem cell transplantation (allo-HSCT), the first cell based gene therapy product approved for cancer patients in Europe (Bonini et al Science 1997, Bonini et al Nat Med 2003; Ciceri et al Blood 2007; Ciceri, Bonini et al Lancet Oncol 2009; Vago et al Blood 2012; Oliveira et al STM 2015).

Today, the lab is focused on the application of genome editing technologies to redirect T cell specificity and function (Provasi, Genovese et al., Nat Med 2012; Mastaglio et al., Blood 2017; Ruggiero et al., STM 2022, Cianciotti et al., Front Immunol, 2024). In recent years the experience gained in the context of T cell therapy for hematological malignancies has been translated to face the challenge of solid tumors. Through an Institutional collaborative effort, involving 18 clinical and preclinical research teams in the Institute, and through dedicated funding from AIRC5x1000, we set up a pipeline of new advanced therapeutic medicinal products (ATMPs) designed for patients with liver metastases from CRC and PDAC (ie: Potenza, Balestrieri et al., GUT 2023 https://research.hsr.it/en/divisions/immunology-transplantation-and-infectious-diseases/airc-5x1000-advanced-therapies-for-liver-metastases.html).

The lab has an Immunomonitoring sub-Unit dedicated to the analyses of immunological correlates with clinical outcome in the context of allo-HSCT (Cieri et al Blood 2015; Tassi, Noviello et al Haematologica 2023; Noviello et al Blood Adv 2023), cellular therapy gene therapy (Biasco et al STM 2015).

As Chair of the Cellular Therapy and Immunobiology Working Party of EBMT (2014-2018) I worked at a European Cellular Therapy Registry, that has now collected data from >8000 patients who received CAR-T cells in Europe and received a regulatory qualification from EMA. As a member of the EHA board of Director, I am actually involved in the GoCART Coalition (https://thegocartcoalition.com) aimed at fostering the access to engineered T cells by cancer patients.

My major aim is to actively participate to the exciting transition of cellular therapy from the investigational phase to the phase of real life by developing and validating at preclinical and clinical level innovative cellular therapy products for cancer and autoimmune diseases.